Literature DB >> 34526871

Dupuytren's Disease: An Outcomes-Focused Update.

Yasser H Almadani1, Joshua Vorstenbosch1, Johnny Ionut Efanov2, Liqin Xu1.   

Abstract

Dupuytren's disease (DD) remains a common fibroproliferative condition with significant sequelae and impact on patient's lives. The etiology of DD is poorly understood, and genetic predisposition is thought to be a strongly associated factor. Despite remarkable strides in improving our molecular understanding of DD, clinical treatment options have not yet overcome the frequently encountered challenge of recurrence. Recurrence rates continue to shape the prognosis of this fibrotic condition. In this outcomes-focused article, the various treatment modalities are reviewed. This further emphasizes the importance of patient education and providing them with the information to make informed decisions about their treatment. Thieme. All rights reserved.

Entities:  

Keywords:  Dupuytren's disease; collagenase injection; needle aponeurotomy; open fasciectomy

Year:  2021        PMID: 34526871      PMCID: PMC8432989          DOI: 10.1055/s-0041-1731631

Source DB:  PubMed          Journal:  Semin Plast Surg        ISSN: 1535-2188            Impact factor:   2.195


  67 in total

1.  Dupuytren'S disease affecting the thumb and first web of the hand.

Authors:  R H Milner
Journal:  J Hand Surg Br       Date:  2003-02

2.  Revised Tubiana's staging system for assessment of disease severity in Dupuytren's disease-preliminary clinical findings.

Authors:  Sandip Hindocha; John K Stanley; James Stewart Watson; Ardeshir Bayat
Journal:  Hand (N Y)       Date:  2007-09-11

Review 3.  Percutaneous fasciotomy for Dupuytren's contracture.

Authors:  Charles Eaton
Journal:  J Hand Surg Am       Date:  2011-05       Impact factor: 2.230

4.  Collagenase Treatment of Dupuytren's Disease with Minimum 5-Year Follow-Up: Recurrence, Reintervention, and Satisfaction.

Authors:  Dafang Zhang; Brandon E Earp; Kyra A Benavent; Philip Blazar
Journal:  Plast Reconstr Surg       Date:  2020-11       Impact factor: 4.730

5.  Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease.

Authors:  David Gilpin; Stephen Coleman; Stephen Hall; Anthony Houston; Jeff Karrasch; Nigel Jones
Journal:  J Hand Surg Am       Date:  2010-12       Impact factor: 2.230

6.  An insight into Dupuytren's contracture.

Authors:  G A Murrell
Journal:  Ann R Coll Surg Engl       Date:  1992-05       Impact factor: 1.891

7.  Dupuytren Contracture Recurrence Following Treatment With Collagenase Clostridium histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-Year Data.

Authors:  Clayton A Peimer; Philip Blazar; Stephen Coleman; F Thomas D Kaplan; Ted Smith; Tommy Lindau
Journal:  J Hand Surg Am       Date:  2015-06-18       Impact factor: 2.230

Review 8.  Pearls and pitfalls of needle aponeurotomy in Dupuytren's disease.

Authors:  Michael Morhart
Journal:  Plast Reconstr Surg       Date:  2015-03       Impact factor: 4.730

Review 9.  Dupuytren contracture as a sign of systemic disease.

Authors:  Ivan Bogdanov; Christopher Rowland Payne
Journal:  Clin Dermatol       Date:  2019-07-31       Impact factor: 3.541

Review 10.  A systematic review and meta-analysis on the prevalence of Dupuytren disease in the general population of Western countries.

Authors:  Rosanne Lanting; Dieuwke C Broekstra; Paul M N Werker; Edwin R van den Heuvel
Journal:  Plast Reconstr Surg       Date:  2014-03       Impact factor: 4.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.